Anexelekto (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study
{{output}}
Introduction: Relapsed/refractory (R/R) acute myeloid leukaemia (AML) is a life-threatening haematological malignancy without effective treatments. Anexelekto (Axl) and Mer receptor tyrosine kinases have emerged as important ther... ...
